C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A01K 67/027 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) A61P 37/04 (2006.01) C07H 21/00 (2006.01) C07K 7/06 (2006.01) C07K 14/705 (2006.01) C07K 16/30 (2006.01) C12N 9/00 (2006.01) C12N 9/02 (2006.01) C12N 15/52 (2006.01) C12N 15/53 (2006.01) C12Q 1/02 (2006.01) C12Q 1/68 (2006.01) G01N 33/574 (2006.01)
Patent
CA 2245702
The present invention discloses that the normal melanogenic gene, gp75 gene, encodes a gene product, a 24 amino acid peptide of ORF3, which is processed to an antigenic cancer peptide recognized by T lymphocytes. The cancer peptide of the invention derived from ORF3 is recognized by cancer antigen specific T lymphocytes as a tumor rejection antigen. The present invention relates to the identification of a second tumor antigen recognized by an HLA-A31 restricted CTL clone derived from the TIL586 cell line. This antigen derived from the TRP- 2 protein tumor antigen and peptides thereof are capable of sensitizing target cells for lysis by a CTL clone at 1 nM peptide concentration. Modified peptides were also recognized by the CTL clone. The products of these genes are promising candidates for immunotherapeutic strategies for the treatment and diagnosis of patients with cancer.
La présente invention révèle que le gène mélanogénique normal, gène gp75, code un produit génique, un peptide à 24 acides aminés de ORF3, lequel est traité en un peptide du cancer antigénique reconnu par les lymphocytes T. Le peptide du cancer de l'invention dérivé de ORF3 est reconnu par des lymphocytes T spécifiques aux antigènes du cancer comme étant un antigène de rejet des tumeurs. La présente invention concerne l'identification d'un second antigène tumoral reconnu par un clone de lymphocytes T cytotoxiques à restriction HLA-A31 dérivé de la lignée cellulaire TIL586. Cet antigène dérivé de l'antigène tumoral de protéine TRT-2 et ses peptides sont capables de sensibiliser des cellules cibles destinées à une lyse par un clone de lymphocytes T cytotoxiques, à une concentration peptidique de 1nM. Le clone de lymphocytes T cytotoxiques a également reconnu des peptides modifiés. Les produits de ces gènes sont des candidats prometteurs pour des stratégies immunothérapeutiques de traitement et de diagnostic de patients atteint du cancer.
Rosenberg Steven A.
Wang Rong-Fu
Department Of Health And Human Services The Government Of The United States Of America As Represented By
Smart & Biggar
LandOfFree
Human cancer antigen of tyrosinase-related protein 1 and 2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human cancer antigen of tyrosinase-related protein 1 and 2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human cancer antigen of tyrosinase-related protein 1 and 2... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2076505